REG - Venture Life Group - Exercise of Options, Director Dealings & TVR

Venture LifeAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260102:nRSB3670Na&default-theme=true

RNS Number : 3670N  Venture Life Group PLC  02 January 2026

2 January 2026

 

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Group")

Exercise of Options, Director Dealings and Total Voting Rights

 

Venture Life Group PLC (AIM: VLG), a recognised leader in proactive healthy,
product innovation, development, and commercialisation within the global
consumer healthcare sector, announces that on 31 December 2025 it issued
483,333 new ordinary shares of 0.3 pence each in the capital of the Company
("Ordinary Shares") following an exercise of options by Jerry Randall, Chief
Executive Officer of the Company, pursuant to the Company's Long-Term
Incentive Plan ("LTIP").

The options were exercised at a price of 41.0 pence per Ordinary Share and
were due to expire on 31 December 2025. Following the option exercise, Jerry
Randall beneficially holds 2,736,533 Ordinary Shares representing
approximately 2.13 per cent. of the Company's issued share capital.

Application will be made to the London Stock Exchange for 483,333 new Ordinary
Shares to be admitted to trading on AIM ("Admission") and it is expected that
Admission will become effective, and trading will commence at 8.00 a.m. on 7
January 2025.

Assuming no further repurchases of Ordinary Shares pursuant to the Company's
buyback programme announced on 30 September 2025 prior to Admission, the total
number of Ordinary Shares in issue on Admission will be 128,737,145, with
1,739,981 Ordinary Shares held in treasury. Therefore, the total number of
voting rights will be 126,997,164. This figure may be used by shareholders as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the FCA's Disclosure and Transparency
Rules.

 

For further information, please contact:

Venture Life Group
PLC
                +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and Broker)
                         +44 (0) 20 7720 0500

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales)

 

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
commercialising products for the global self-care market. Headquartered in
the UK, the Group's product portfolio includes Balance Activ in the area of
women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, plus the
Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through health & beauty stores,
pharmacies, grocery multiples and e-commerce channels and are sold globally.
In the UK,  Ireland and the USA these are supplied direct by the company to
retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

The Company makes the following disclosure in accordance with article 19(3) of
the Market Abuse Regulation:

 1    Details of the person discharging managerial responsibilities / person closely

    associated


 a)   Name                                                         Jerry Randall

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Venture Life Group plc

 b)   LEI                                                          213800S8CZUPLAB2KC70

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.3p each in Venture Life Group plc

      Identification code

                                                                   GB00BFPM8908
 b)   Nature of the transaction                                    Exercise of share options

 c)   Price(s) and volume(s)

Price       Volume
                                                                   41.0 pence  483,333

 d)   Aggregated information                                       N/A - Single transaction

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      31 December 2025

 f)   Place of the transaction                                     Outside of a trading venue

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

N/A - Single transaction

 

 

 

 

 

 

e)

 

Date of the transaction

 

31 December 2025

f)

 

Place of the transaction

 

Outside of a trading venue

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEAKDBNKBKDODK



            Copyright 2019 Regulatory News Service, all rights reserved